scholarly journals Metabolismo Óseo

2019 ◽  
Vol 6 (2S) ◽  
pp. 85-90
Author(s):  
Asociación Colombiana de Endocrinología Diabetes y Metabolismo
Keyword(s):  
Clinical Trial ◽  
Osteoporotic Fractures ◽  
Patient Characteristics ◽  
Post Hoc Analysis ◽  
Vitamina D ◽  
Major Osteoporotic Fractures ◽  
Resistencia A La Insulina ◽  
Factores De Riesgo ◽  
Previously Treated ◽  
Post Hoc

Listado: Bajos niveles de vitamina D y su relación con la alteración de lípidos sanguíneos en mujeres posmenopáusicas de 2 municipios del departamento del Atlántico.  Becerra JE, Rebolledo RC, Pabón AC, Suárez M, Sarmiento LA. Déficit de vitamina D en hombres y mujeres con deseo sexual hipoactivo. Estudio de prevalencia.   Espitia F, Orozco L. Determinación del consumo diario de calcio en la población colombiana.   Arenas HM, Arias D, López VJ, Arias DR. Efficacy of Teriparatide Compared with Risedronate on Frax®- Defined Major Osteoporotic Fractures: a Post-Hoc Analysis of the VERO Clinical Trial.   Body JJ1 , Marin F2 , Geusens P3 , Zerbini C4 , FahrleitnerPammer A5 , Moericke R6 , et al. Osteoporosis y baja masa ósea en mediciones de densitometría en Villavicencio, Meta, durante el 2018.   Rosero FO, Garcés H, Beltrán A, Guerrero JF, Escobar LM, Galeano D, et al. Osteoporosis, sarcopenia y correlación entre SARC-F y masa muscular por DXA en población colombiana: estudio piloto.   Castrillón MP, Flórez AM, Vergara JE, Roa A, Quintero J, Parra G, et al. Patient Characteristics and Fracture Outcomes in Patients Previously Treated with Bisphosphonates or TreatmentNaïve in The Teriparatide Versus Risedronate VERO Clinical Trial.   Hadji P1 , Marin F2 , Kendler DL3 , Geusens P4 , Russo L5 , Malouf J6 , et al. Prevalencia del déficit de vitamina D y factores de riesgo asociados en gestantes del Quindío.   Espitia F, Orozco L. Prevalencia del déficit de vitamina D en mujeres posmenopáusicas de Armenia.   Espitia F, Orozco Santiago L. Relación entre el índice TG/ HDL-C, la resistencia a la insulina y la vitamina D sérica en mujeres posmenopáusicas del departamento del Atlántico, Colombia.   Sarmiento LA1 , Becerra JE1 , Rebolledo R2 , Suárez M1 , Barragán M1 , Sánchez L1 Tabaquismo y vitamina D: una vía a la fragilidad.   Pérez MU1, 2, Patiño D1, 3, Borda MG1, 4.

scholarly journals Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS

2021 ◽  
Author(s):  
Andrea Giaccari ◽  
R. C. Bonadonna ◽  
R. Buzzetti ◽  
G. Perseghin ◽  
D. Cucinotta ◽  
...  
Keyword(s):  
Glycaemic Control ◽  
Insulin Glargine ◽  
Patient Characteristics ◽  
Efficacy And Safety ◽  
Clinical Trial Registration ◽  
Post Hoc Analysis ◽  
Almost All ◽  
Antihyperglycaemic Drugs ◽  
Post Hoc ◽  
Patient Subgroups

Abstract Aims The Italian Titration Approach Study (ITAS) demonstrated comparable HbA1c reductions and similarly low hypoglycaemia risk at 6 months in poorly controlled, insulin-naïve adults with T2DM who initiated self- or physician-titrated insulin glargine 300 U/mL (Gla-300) in the absence of sulphonylurea/glinide. The association of patient characteristics with glycaemic and hypoglycaemic outcomes was assessed. Methods This post hoc analysis investigated whether baseline patient characteristics and previous antihyperglycaemic drugs were associated with HbA1c change and hypoglycaemia risk in patient- versus physician-managed Gla-300 titration. Results HbA1c change, incidence of hypoglycaemia (any type) and nocturnal rates were comparable between patient- and physician-managed arms in all subgroups. Hypoglycaemia rates across subgroups (0.03 to 3.52 events per patient-year) were generally as low as observed in the full ITAS population. Small increases in rates of 00:00–pre-breakfast and anytime hypoglycaemia were observed in the ≤ 10-year diabetes duration subgroup in the patient- versus physician-managed arm (heterogeneity of effect; p < 0.05). Conclusions Comparably fair glycaemic control and similarly low hypoglycaemia risk were achieved in almost all patient subgroups with patient- versus physician-led Gla-300 titration. These results reinforce efficacy and safety of Gla-300 self-titration across a range of phenotypes of insulin-naïve people with T2DM. Clinical trial registration EudraCT 2015-001167-39

scholarly journals Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1284
Author(s):  
Nicolas Delanoy ◽  
Debbie Robbrecht ◽  
Mario Eisenberger ◽  
Oliver Sartor ◽  
Ronald de Wit ◽  
...  
Keyword(s):  
Progression Free Survival ◽  
Phase Iii ◽  
Castration Resistant Prostate Cancer ◽  
Radiological Progression ◽  
Post Hoc Analysis ◽  
Psa Response ◽  
Phase Iii Study ◽  
Psa Progression ◽  
Previously Treated ◽  
Post Hoc

Background: In the PROSELICA phase III trial (NCT01308580), cabazitaxel 20 mg/m2 (CABA20) was non-inferior to cabazitaxel 25 mg/m2 (CABA25) in mCRPC patients previously treated with docetaxel (DOC). The present post hoc analysis evaluates how the type of progression at randomization affected outcomes. Methods: Progression type at randomization was defined as follows: PSA progression only (PSA-p; no radiological progression (RADIO-p), no pain), RADIO-p (±PSA-p, no pain), or pain progression (PAIN-p, ±PSA-p, ±RADIO-p). Relationships between progression type and overall survival (OS), radiological progression-free survival (rPFS), and PSA response (confirmed PSA decrease ≥ 50%) were analyzed. Results: All randomized patients (n = 1200) had received prior DOC, and 25.7% had received prior abiraterone or enzalutamide. Progression type at randomization was evaluable in 1075 patients (PSA-p = 24.4%, RADIO-p = 20.8%, PAIN-p = 54.8%). Pain progression was associated with clinical and biological features of aggressive disease. Median OS from CABA initiation or date of mCRPC diagnosis, all arms combined, was shorter in the PAIN-p group than in the RADIO-p or the PSA-p groups (12.0 versus 16.8 and 18.4 months, respectively, p < 0.001). In multivariate analysis, all arms combined, PAIN-p was an independent predictor of poor OS (HR = 1.44, p < 0.001). PSA response, rPFS, and OS were numerically higher with CABA25 versus CABA20 in patients with PAIN-p. Conclusions: This post hoc analysis of the PROSELICA phase III study shows that pain progression at initiation of CABA in mCRPC patients previously treated with DOC is associated with a poor prognosis. Disease progression should be carefully monitored, even in the absence of PSA rise.

Effects of Low-Volume, High-Intensity Interval Training Compared with Continuous Training on Regional and Global Body Composition in Adults with Metabolic Syndrome: A post hoc Analysis of a Randomized Clinical Trial

2021 ◽  
pp. 1-10
Author(s):  
Juan Carlos Aristizabal ◽  
Esperanza Montoya ◽  
Yeliana L. Sánchez ◽  
Manuela Yepes-Calderón ◽  
Raul Narvaez-Sanchez ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Body Composition ◽  
Interval Training ◽  
High Intensity Interval Training ◽  
Continuous Training ◽  
Post Hoc Analysis ◽  
Low Volume ◽  
High Intensity Interval ◽  
Post Hoc

Objective: The aim of this study was to compare the effects of low-volume, high-intensity interval training (HIIT) or moderate-intensity continuous training (MICT) on body composition in adults with metabolic syndrome (MS). Methods: This is a post hoc analysis of the randomized clinical trial Intraining-MET. Sixty adults (40–60 years old) were randomized to an MICT (n = 31) or HIIT (n = 29) supervised programme 3 days/week for 12 weeks. MICT sessions were conducted for 36 min at 60% of peak oxygen consumption (VO2peak). HIIT sessions included 6 intervals at 90% VO2peak for 1 min, followed by 2 min at 50% VO2peak. Body composition was assessed with dual energy X-ray absorptiometry. Results: Body weight did not change from pre- to post-training in either MICT (78.9 ± 15.6 kg; 77.7 ± 16.5 kg, p = 0.280) or HIIT groups (76.3 ± 13.4 kg; 76.3 ± 13.7 kg, p = 0.964). Body fat percentage and fat mass (FM) decreased post-training in the MICT (−0.9%; 95% confidence interval [CI]: −0.27 to −1.47 and −0.7 kg; 95% CI: −0.12 to −1.30) and HIIT groups (−1.0%; 95% CI: −0.32 to −1.68 and −0.8 kg; 95% CI: −0.17 to −1.47). Compared to the HIIT programme, MICT significantly reduced android FM (−0.14 kg; 95% CI: −0.02 to −0.26). Lean mass (LM) increased post-training in MICT (+0.7 kg; 95% CI: 0.01–1.41) and HIIT groups (+0.9 kg; 95% CI: 0.12–1.64), but only HIIT increased the trunk LM (+0.6 kg; 95% CI: 0.06–1.20). Conclusions: Both MICT and HIIT reduced FM without changing body weight in adults with MS. MICT had additional benefits by reducing the android FM, whereas HIIT seemed to increase LM. Given the characteristics of the post hoc analysis, further research is required to confirm these results.

scholarly journals 08 Evidence Base for Treatment of Osteoporosis in Older People

2019 ◽  
Vol 48 (Supplement_4) ◽  
pp. iv3-iv3
Author(s):  
Tahir Masud
Keyword(s):  
Oldest Old ◽  
Age Groups ◽  
Osteoporotic Fractures ◽  
Osteoporosis Treatment ◽  
Fracture Reduction ◽  
Older Population ◽  
Term Care ◽  
Treatment Of Osteoporosis ◽  
Post Hoc Analysis ◽  
Post Hoc

Abstract After the age of fifty years the prevalence of osteoporosis and incidence of osteoporotic fractures rise substantially with age. It is ironic however that the pivotal trials for the common drugs used to treat osteoporosis mainly recruited participants under the age of 80 years leading some to question the use of these drugs in the older population. This talk explores the evidence accumulated for the treatment of osteoporosis in the frailer older population. The FOSIT trial showed a 47% reduction in non-vertebral fractures with alendronate in people up to 84 years, and a study in long term care in those up to 91 years showed a significant improvement in bone density at the spine and hip. A post hoc analysis of the risedronate HIP trial in people aged 70-100 years with established osteoporosis showed a 47% reduction in hip fractures. In the zoledronic acid Horizon studies fractures were significantly reduced in a population up to the age of 89 years and mortality was reduced by 28%, with half of the participants being older than 75 years. Interestingly a post hoc analysis showed that those participants who ended up having only a single infusion had a reduction of all clinical fractures at 3 years. The Freedom trial of denosumab was performed in a population aged up to 90 years with significant fracture reduction across all age groups. Studies with the anabolic agent teriparatide showed that vertebral and non-vertebral fracture reduction occurred in both the under and over 75 age groups. Trials with the recently developed agents abaloparatide and romosozumab have shown significant fracture reductions in populations up to ages of 86 and 90 years respectively. There is now enough evidence to suggest that the oldest old should be considered for osteoporosis treatment as well having a focus on falls reduction.

Sign in / Sign up

Export Citation Format

Share Document